Company intelligence / Profile preview
Tactiva Therapeutics
Buffalo, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Tactiva Therapeutics is developing next-generation adoptive cell therapies that leverage both CD4 and CD8 TCRs from genetically reprogrammed patient T cells and hematopoietic stem cells. Their preclinical data demonstrate potent and sustained tumor control by combining the direct cytotoxic effects of CD8-TCRs with the helper and direct tumor-killing capabilities of CD4-TCRs, aiming for durable remission in solid tumors[3][9].
- Therapeutic areas
- Oncology
- Modalities
- T cell receptor engineered T cell therapyOncolytic virus therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Roswell Park Cancer Institute (technology licensing)
Beyond the preview
Go deeper on Tactiva Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tactiva Therapeutics.